Retina

Tylectomy indicates surgical resection of retinoblastomas via pars plana vitrectomy with intraoperative chemotherapy infusion.

Paul Kayne, PhD gave an onsite overview of his poster at the 2024 ARVO meeting

At the ARVO meeting in Seattle, Washington, the Eye Care Network spoke with Giulia Corradetti, MD about AMD

Paolo Silva, MD, speaks on the effect of diabetic retinopathy lesion location and long-term risk of progression

Barry Kuppermann, MD, PhD, director of the Gavin Herbert Eye Institute at the University of California Irvine, speaks about his ARVO poster presentation

Qinqin Zhang, PhD, presented on a deep learning model for GA segmentation at this year's ARVO meeting

At this year's ARVO meeting, Ash Abbey, MD, presented 36-month data from the GALE study of pegcetacoplan

Study results indicate that maintaining control of blood pressure and hemoglobin A1c are key to preventing the onset of diabetic retinopathy

Study data demonstrated a significant correlation between visual function, structure and neurological impairment in an experimental autoimmune encephalomyelitis model

The 18th annual Controversies in Modern Eye Care conference, held on May 4, 2024, in Los Angeles, was co-chaired by Neda Shamie, MD, and Arjan Hura, MD, with the aim of discussing the latest advancements in eye care.

Hura highlighted some of the key takeaways from the Controversies in Modern Eye Care symposium where presenters and attendees shared their insights into the latest advancements in refractive surgery, retina care, and collaborative eye care.

The diagnostic screening technology is able to diagnose diabetic retinopathy by using 1 image taken of each eye with over 99% imageability.

According to the company, a subretinal injection of ATSN-201 was well tolerated in all patients in the first cohort with extensive resolution of schisis observed in 2 patients. Safety data from the first cohort of the LIGHTHOUSE study will be presented at the Retinal Cell and Gene Therapy Innovation Summit 2024 being held May 3, 2024, in Seattle.

The tool shows disease progression and vision loss simulations for multiple diseases such as AMD, XLRP, and achromatopsia

During the month of May, Prevent Blindness will offer fact sheets, videos and other resources for IRD education

Gildeuretinol halts Stargardt disease progression, study results indicate

The collaboration will bring automated, AI-powered OCT segmentation to MICRON Software Suite.

CRISPR manipulation presents opportunities and challenges.

The online tool shows vision loss simulations for diabetic macular oedema, diabetic retinopathy, age-related macular degeneration and other retinal diseases

Prof Tadayoni was a much-admired leader, researcher, surgeon and EURETINA President

SGT-1001 uses its novel gene coding technology for gene integration via transposition. It plans to advance SGT-1001 into the clinic in the first half of 2025.

Shift could lead to changes in the current management of retinal diseases

According to the company, 46.2% of patients demonstrated a 1- or 2-step improvement in the Diabetic Retinopathy Severity Scale (DRSS) at 40 weeks in the Axpaxli arm, compared to 0% in the control arm.

According to the company, the grant funding from the Choroideremia Research Foundation is in support of validating functional vision assessments for patients with profound blindness.

The company’s AI technology uses retinal imaging to assess potential health risks in patients.